Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells

• Published in: Leukemia Vol. 11; no. 9; pp. 1516 - 1522
• Main Authors: ZHOU, D.-C, SIMONIN, G, FAUSSAT, A.-M, ZITTOUN, R, MARIE, J.-P
• Format: Journal Article
• Language: English
• Published: London Nature Publishing 01.09.1997; Nature Publishing Group
• Subjects: Acridines - pharmacology; Acute Disease; Acute myeloid leukemia; Antineoplastic agents; ATP-Binding Cassette, Sub-Family B, Member 1 - genetics; Biological and medical sciences; Cell Membrane Permeability - drug effects; Clinical trials; Daunorubicin; Drug Resistance, Multiple; Gene Expression - drug effects; General aspects; Humans; Idarubicin - administration & dosage; Incubation; Isoquinolines - pharmacology; Leukemia; Leukemia - drug therapy; MDR1 protein; Medical sciences; Mitoxantrone; Mitoxantrone - administration & dosage; Modulation; P-Glycoprotein; Pharmacology. Drug treatments; Phenotypes; Rhodamine; RNA, Messenger - genetics; RNA, Neoplasm - genetics; Sensitivity; Tetrahydroisoquinolines; Toxicity; Tumor Cells, Cultured; Verapamil; Verapamil - pharmacology; Antineoplastic agent; Cytotoxicity; Myeloproliferative syndrome; Daunorubicin; Lymphoproliferative syndrome; Multiple resistance; Chronic myelocytic leukemia; Established cell line; Drug interaction; Acute lymphocytic leukemia; Mitoxantrone; Negative therapeutic reaction; Human; Promyelocytic leukemia; Drug combination; Anthraquinone derivatives; Acute; Malignant hemopathy; In vitro; HL60 cell line; Alkylating agent; Antibiotic; Chronic; Antimetabolic; Analog; Carboxamide; Reversibility; Anthracyclins; Idarubicin; Acute myelocytic leukemia

The drug GG918 has been specifically developed for overcoming MDR phenotype and is now in use in clinical trials. In this study, the effects of GG918 on leukemic cell were investigated using a 3 day MTT assay. Results showed that, in a highly resistant P-gp(+) leukemic cell line, 0.1 microM of GG918...